Moderna (MRNA) Stock Recovers Angela Merkel Apposes patent waivers

Moderna Inc (NASDAQ:MRNA) stock is recovering from lows a bit in recent trade following a report that German Chancellor Angela Merkel is against patent waivers for COVID-19 vaccines.

Moderna (MRNA) Stock Recovers Angela Merkel Apposes patent waivers

MRNA stock has fallen about 17% from yesterday’s high following the report that USTR Katherine Tai will have talks about intellectual property waiver regarding COVID-19 vaccines.

Moderna is all set to report its first-quarter earnings today. Analysts are estimating the company report EPS of $2.30 compared to a loss of 35 cents in the same quarter of the last year.

Related:  Sundial Growers (SNDL) Moves Back Above $1 in Momentum Trade

Revenue is expected to jump on sales of Moderna’s recently approved COVID-19 vaccine. Moderna expects to supply up to 1 billion doses of its vaccine in 2021.

MRNA stock is just down 2.60% at $158.61 after falling to a low of $143.56.

 

 

Jack Dawkins

Finance and Tech Contributor